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OBJECTIVE—People with the HLA genotype DRB1*0301-
DQA1*0501-DQB1*0201/DRB1*04-DQA1*0301-DQB1*0302 (DR3/
4-DQ8) are at the highest risk of developing type 1 diabetes.
We sought to ﬁnd an inexpensive, rapid test to identify
DR3/4-DQ8 subjects using two single nucleotide polymor-
phisms (SNPs).
RESEARCH DESIGN AND METHODS—SNPs rs2040410 and
rs7454108 were associated with DR3-DQB1*0201 and DR4-
DQB1*0302. We correlated these SNPs with HLA genotypes and
with publicly available data on 5,019 subjects from the Type 1
Diabetes Genetic Consortium (T1DGC). Additionally, we ana-
lyzed these SNPs in samples from 143 HLA-typed children who
participated in the Diabetes Autoimmunity Study of the Young
(DAISY) using Taqman probes (rs7454108) and restriction digest
analysis (rs2040410).
RESULTS—With a simple combinatorial rule, the SNPs of
interest identiﬁed the presence or absence of the DR3/4-DQ8
genotype. A wide variety of genotypes were tested for both SNPs.
In T1DGC samples, the two SNPs were 98.5% (1,173 of 1,191)
sensitive and 99.7% (3,815 of 3,828) speciﬁc for DR3/4-DQ8. In the
DAISY population, the test was 100% (69 of 69) sensitive and
100% (74 of 74) speciﬁc. Overall, the sensitivity and speciﬁcity for
the test were 98.57 and 99.67%, respectively.
CONCLUSIONS—A two-SNP screening test can identify the
highest risk heterozygous genotype for type 1 diabetes in a time-
and cost-effective manner. Diabetes 57:3152–3155, 2008
W
e have the ability to identify subjects with a
greater than 50% risk of developing anti-islet
autoimmunity and type 1 diabetes on the
basis of family history and HLA genotype
(1,2). Siblings with the highest type 1 diabetes risk HLA
genotype DRB1*0301-DQA1*0501-DQB1*0201/DRB1*04-
DQA1*0301-DQB1*0302 (DR3/4-DQ8) who are identical by
descent for the major histocompatibility complex region
with a type 1 diabetic sibling have an 85% risk of develop-
ing diabetes-related autoimmunity by age 15 years and a
55% risk of developing type 1 diabetes by age 12 years (1).
Children with multiple ﬁrst-degree relatives with type 1
diabetes and high– or moderate–diabetes risk HLA geno-
types are reported to have a 50% risk for the development
of multiple diabetes-related autoantibodies and type 1
diabetes (2).
Prevention trials, including the Trial to Reduce Type 1
Diabetes in the Genetically at Risk (TRIGR) (3), the
Nutritional Intervention to Prevent Diabetes (NIP-Diabe-
tes) trial (4), and the Primary Oral and Intranasal Trial
(Pre-POINT) are currently underway in genetically at-risk
children. Many of these trials include ﬁrst-degree relatives
of people with diabetes as well as individuals with high-
risk HLA genotypes, including DR3/4-DQ8. The identiﬁca-
tion of subjects for these trials requires large-scale HLA
screening, with many children tested who do not have the
highest type 1 diabetes risk. Current typing techniques for
DR3/4-DQ8 often utilize coampliﬁcation of the DQA1 and
DQB1 genes followed by multiple probe hybridization or
direct sequencing. This technique uses sequence-speciﬁc
oligonucleotides in a linear assay for hybridization with
ampliﬁed product from DNA samples (5). Alleles are
called with a customized typing program. Sequence-based
typing techniques use PCR to amplify DRB1 genes that are
sequenced, with HLA type determined using special soft-
ware (6). High-throughput screening systems that em-
ploy asymmetric PCR and hybridization of allele-
speciﬁc probes as a ﬁrst screening step to identify
samples with speciﬁed HLA genotypes have been devel-
oped. Samples identiﬁed via these programs can be
identiﬁed for further HLA genotyping (7). This method is
cost and time consuming, as it may cost up to $31.44 to
genotype 1 sample and takes up to9ht op erform and
analyze a set of 50 samples.
Several studies have examined the possibility of predict-
ing HLA alleles from existing single nucleotide polymor-
phism (SNP) data (8–10); however, only one article has
provided data on predicting speciﬁc HLA alleles from
individual SNPs. de Bakker et al. (8) reported an associa-
tion between HLA types and SNPs. SNP rs2040410 A allele
was associated with DRB1*0301, and rs7454108 C allele
with DQB1*0302. We have developed and tested the ability
of these two SNPs to identify individuals with the DR3/4-
DQ8 genotype in subjects within the Type 1 Diabetes
Genetics Consortium (T1DGC) and the Diabetes Autoim-
munity Study in the Young (DAISY). This novel method
adds to existing knowledge by utilizing SNP technology to
quickly identify individuals with the DR3/4-DQ8 genotype
and may be beneﬁcial to prevention trials because it
provides high-throughput screening in a time- and cost-
effective manner.
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The T1DGC enrolled sibling pairs with type 1 diabetes and their parents. HLA
typing and two standard dense Illumina SNP panels of the major histocom-
patibility complex region were completed. We ﬁrst evaluated 344 Polish
subjects from the T1DGC, as this was the original dataset available to our
group. We expanded the analysis to an additional ﬁve T1DGC cohorts—British
Diabetic Association (n  1,911), Denmark (n  776), Human Biological Data
Interchange (n  2,605), Joslin Diabetes Center (n  486), and U.K. (n 
519)—totaling 6,297 subjects from 1,240 families (Table 1). Subjects were
enrolled with informed consent, and the study was approved by the local
institutional review board or ethics committee.
We typed 143 subjects with a variety of HLA-DR/DQ genotypes from
DAISY. DAISY has HLA-typed more than 30,000 newborns in Denver, Colo-
rado, at the HLA-DR/DQ loci (11,12) and has followed a subset of these
children with high, intermediate, and low risk with measurement of autoan-
tibody levels (insulin, GAD65, and [insulinoma-associated protein 2] IA-2)
(12). DAISY also follows a cohort of siblings and offspring of patients with
type 1 diabetes. Subjects were enrolled with informed parental consent, and
the study was approved by the institutional review board at the University of
Colorado Denver.
Typing of SNPs. T1DGC samples were typed with Illumina multiplex
technology with an extension/ligation reaction (details available at the Illu-
mina Technology and Applications Web site [www.illumina.com]). This anal-
ysis utilized the dense standard Illumina mapping and exon-centric panels
(1,536 SNPs in each panel with 115 overlapping SNPs; 2,837 of 3,072 SNPs
successfully typed with a 92% SNP locus success rate). Both SNPs (rs7454108
and rs2040410) we used to identify DR3/4-DQ8 individuals were included
in the Illumina panel. There were no data for rs2040410 in the Joslin T1DGC
Illumina panels; therefore, individuals from that cohort were excluded.
We utilized two typing techniques to analyze the individual SNPs rs7454108
and rs2040410 in DAISY samples. We genotyped 143 samples for rs7454108
using Taqman probes (hybridization/extension reaction with a ﬂuorescence
detection system developed by Applied Biosystems). Given nearby polymor-
phisms, we were unable to use Taqman technology to analyze rs2040410 and
instead utilized restriction enzyme digestion.
We designed primers to sequence the region surrounding rs2040410 after
identifying known SNPs in the region (forward: 5 TGT GCT GAG AGT TCC
AGC CT 3; reverse: 5 CAC AAG GAC TCA TGG CTT GG 3). We genotyped
40 samples at the rs2040410 SNP using the 3130 Capillary Sequencing Machine
(BigDye Terminator v1.1, Applied Biosystems). A restriction enzyme site that
distinguished the two alleles for this SNP was identiﬁed (BsrGI, digested for
at least 16 h at 37°C; New England BioLabs). The restriction digest showed
100% correlation with the sequencing and was used to complete typing for
rs2040410 in 119 samples.
HLA genotyping. We performed DRB1 and DQB1 genotyping on DAISY
samples using linear arrays of immobilized sequence-speciﬁc oligonucleotides
similar to previously described methodology (5).
Statistical analysis. We performed two-by-two contingency analysis (Fish-
er’s exact test) and determined the sensitivity and speciﬁcity of the two
marker SNPs for identifying the DR3/4-DQ8 genotype in previously typed
individuals.
RESULTS
Figure 1 illustrates the location of rs2040410 (R
2 for
DRB1*0301  0.872) (8) and rs7454108 (R
2 for
DQB1*0302  1.0) (8) in relation to classical HLA genes.
The rs2040410 A allele is associated with DRB1*0301, and
the rs7454108 C allele is associated with DQB1*0302. We
hypothesized that subjects with HLA genotype DR3/4-DQ8
would have the SNP genotype AG/CT. Of 6,641 T1DGC
subjects, 5,019 (75.6%) had HLA genotyping and data for
the SNPs of interest. Of the 1,191 subjects with DR3/4-
DQ8, 1,121 (94.1%) had AG/CT and 52 (4.6%) had AA/CT.
Of the 3,828 subjects that were not DR3/4-DQ8, only 12
(0.3%) had the genotype AG/CT and 1 (0.03%) had the
genotype AA/CT. Using the two genotypes AG/CT and
AA/CT as markers of the DR3/4-DQ8 genotype, we identi-
ﬁed subjects with DR3/4-DQ8 with 98.5% sensitivity and
99.7% speciﬁcity (Table 2). Of the 13 false-positives, 4
(30.8%) were DRB1*0301 and DQB1*0302 but not DR4-
TABLE 1
Characteristics by cohort
n Probands Parents DR3/4-DQ8
Not
DR3/4-DQ8
Sensitivity
DR3/4-DQ8 (n)
Speciﬁcity not
DR3/4-DQ8 (n)
BDA 1,598 772 737 429 1,169 97.67% (419 of 429) 99.23% (1,160 of 1,169)
Denmark 675 309 228 150 525 98.67% (148 of 150) 99.81% (524 of 525)
HBDI 2,037 894 828 433 1,604 98.61% (427 of 433) 99.88% (1,602 of 1,604)
Poland 344 126 218 62 282 100.00% (62 of 62) 99.65% (281 of 282)
U.K. 365 182 151 117 248 100.00% (117 of 117) 100.00% (248 of 248)
DAISY 143 NA NA 69 74 100.00% (69 of 69) 100.00% (74 of 74)
N 5,162 2,283 2,162 1,260 3,902 98.57% (1,242 of 1,260) 99.67% (3,889 of 3,902)
Data are n unless otherwise indicated. BDA, British Diabetic Association; HBDI, Human Biological Data Interchange.
FIG. 1. Location of SNPs () in relation to classical HLA loci (A) and HLA-DRB1 and -DQB1 loci (B). Numbers are distance in megabase (Mb)
pairs from the telomere.
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In analysis of the British Diabetic Association cohort
with DR3/4-DQ8, 87.4% (376 of 429) of subjects had the
genotype AG/CT and 10.0% (43 of 429) had the genotype
AA/CT, compared with 97.8% (745 of 762) and 1.18% (9 of
762), respectively, in the other cohorts (P  0.0001). The
unique frequency of the AA genotype of rs2040410 with the
DR3/4-DQ8 genotype in this population suggests popula-
tion differences within the U.K., as the U.K. cohort did not
have increased frequency of the AA rs2040410 genotype.
Of the 2,162 parents in the T1DGC population, 200 were
DR3/4-DQ8 and 97.0% (194 of 200) were AA/CT or AG/CT,
while 99.7% (1,956 of 1,962) of subjects that were not
DR3/4-DQ8 were not AA/CT or AG/CT. There were 2,283
probands in this population; 99.0% (901 of 910) of DR3/4-
DQ8 probands were AA/CT or AG/CT, and 99.5% (1,366 of
1,373) of non–DR3/4-DQ8 probands were not AA/CT or
AG/CT.
We evaluated 143 subjects in the DAISY study, 69 with
DR3/4-DQ8. Subjects were chosen to represent a wide
range of HLA genotypes, with a focus on DR3/4-DQ8
individuals (Online Appendix Table 2). All 69 subjects with
DR3/4-DQ8 were AG/CT, and none of the subjects without
DR3/4-DQ8 were AG/CT or AA/CT. Using the two geno-
types AG/CT and AA/CT as markers of the DR3/4-DQ8
genotype, we identiﬁed subjects with DR3/4-DQ8 with
100% sensitivity and speciﬁcity (Table 1).
Overall, the sensitivity of the test was 98.57% and the
speciﬁcity was 99.67% (Table 1). The rs2040410 A allele
was present in 2,921 of the 3,018 (96.8%) individuals with
DRB1*0301. The rs7454108 C allele was present in 3,315 of
the 3,353 (98.9%) individuals with DQB1*0302.
DISCUSSION
In the U.S., approximately 1 in 300 individuals develop
type 1 diabetes by age 18 years (13,14). The incidence of
type 1 diabetes is increasing (15), especially at the young-
est ages (16,17). Type 1 diabetes is characteristically
preceded by the presence of anti-islet autoantibodies (18).
Several groups of individuals have been identiﬁed as
having a risk of type 1 diabetes greater than 50% by genetic
factors alone (1,2). These groups have been proposed as
ideal cohorts for intervention before the onset of autoim-
munity, which may be key because it has proven difﬁcult
to halt the autoimmune process once it begins. Identiﬁca-
tion of these high-risk subjects for clinical trials will
require screening many subjects for HLA genotypes. DR3/
4-DQ8 individuals comprise between 30 and 50% of all
children developing diabetes and thus represent an impor-
tant high-risk group but only a subset of all children
developing diabetes. It is likely that initial trials of immu-
nomodulation (e.g., Pre-POINT) in genetically susceptible
but autoantibody-negative children will primarily enroll
only the highest-risk individuals, such as subsets of those
with DR3/4-DQ8.
We conﬁrmed the observations made by de Bakker et al.
(8) of the association of DRB1*0301 with the A allele of
rs2040410 and DQB1*0302 with the C allele of rs7454108.
We attempted to exploit this association to identify sub-
jects with the highest-risk HLA genotype for type 1 diabe-
tes and were able to discern a variety of DR/DQ genotypes
with our two-SNP test. The Taqman assay was speciﬁc
enough to differentiate DQB1*0301, -0302, -0303, and -0304
in the DAISY population, identifying DR4-DQ8 alleles
exclusively and resulting in excellent speciﬁcity when
both SNPs were evaluated.
We have found that the use of two SNPs can identify
subjects with DR3/4-DQ8 across different populations with
greater than 99% accuracy. The assays can be performed in
most laboratories, results are available within a relatively
short period of time, and the cost of performing these tests
is much less than that of traditional HLA genotyping.
Therefore, we propose an algorithm for the use of the
two-SNP test to identify individuals with a high probability
of the DR3/4-DQ8 genotype (Fig. 2) for further standard
HLA genotyping. Employing this algorithm makes per-
forming standard testing on all subjects unnecessary and
greatly reduces the cost and time required to test a large
group of samples. This would allow rapid and relatively
inexpensive screening of samples for more detailed HLA
genotyping. It is estimated to cost $4 per sample to run the
TaqMan assay and $2.05 per sample to perform the restric-
TABLE 2
Evaluation of rs2040410 and rs7454108 in subjects participating
in the British Diabetic Association, Denmark, Human Biological
Data Interchange, Poland, and U.K. T1DGC cohorts and in
subjects in the DAISY population analyzed by restriction digest
and Taqman
DR3/4-DQ8
Not
DR3/4-DQ8
n 1,191 3,828
T1DGC subjects
rs2040410 A/G and rs7454108 C/T 1,121 (94.1) 12 (0.3)
rs2040410 A/A and rs7454108 C/T 52 (4.4) 1 (0.03)
rs2040410 G/G and rs7454108 C/T 7 (0.6) 1,384 (36.2)
rs2040410 A/G and rs7454108 C/C
or T/T 9 (0.8) 1,086 (28.4)
rs2040410 A/A or G/G and
rs7454108 C/C or T/T 2 (0.2) 1,345 (35.1)
DAISY subjects
rs2040410 A/G and rs7454108 C/T 69 (100) 0 (0)
rs2040410 A/A and rs7454108 C/T 0 (0) 0 (0)
rs2040410 G/G and rs7454108 C/T 0 (0) 27 (36.5)
rs2040410 A/G and rs7454108 C/C
or T/T 0 (0) 16 (21.6)
rs2040410 A/A or G/G and
rs7454108 C/C or T/T 0 (0) 31 (41.9)
Data are n (%) unless otherwise indicated.
rs2040410 restriction digest analysis
rs2040410 A/G or A/A
rs7454108 Taqman® analysis
Consistent with DR3/4-DQ8 
Confirm with HLA genotyping
YES
rs7454108 C/T
YES
NO
NO
Not DQB1*0302
Not DRB1*0301
FIG. 2. Proposed algorithm for identifying subjects with DR3/4-DQ8
with SNP testing.
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cost of traditional HLA genotyping at $31.44 per sample.
To examine the applicability of the two-SNP test in the
general population, we applied Bayes theorem using the
prevalence of DR3/4-DQ8 in the Denver population (2.4%)
(11). In a hypothetical population of 1,000 people, 24
would have DR3/4-DQ8. Using our 98.57% sensitivity and
99.67% speciﬁcity, 23 of these individuals would be iden-
tiﬁed as DR3/4-DQ8 and 3 individuals without the genotype
would be incorrectly classiﬁed as DR3/4-DQ8, giving a
positive predictive value of 87.6% (23 of 26). One individual
with DR3/4-DQ8 would be incorrectly classiﬁed as not and
973 individuals without DR3/4-DQ8 would be correctly
classiﬁed, giving a negative predictive value of 99.9% (973
of 974). The prevalence of the DR3 allele in Denver is
22.7%, yielding a positive predictive value of 93.7% and a
negative predictive value of 99.0% for the rs2040410 A
allele. The prevalence of the DQB1*0302 allele in Denver is
21.9%. The rs7454108 C allele has a positive predictive
value of 97.5% and a negative predictive value of 99.7%.
Although we recommend further traditional typing to
conﬁrm the presence of high-risk genotypes, the positive
predictive value of this two-SNP test is quite high in a
relatively low frequency population and demonstrates the
utility of this two-SNP test.
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